Yeni Bir Antibakteriyel Ajan: DAPTOMİSİN

Yıl 2010, Cilt: 63 Sayı: 3, 85 - 88, 01.03.2010

Gülden Yılmaz Bozkurt Hakan Kutlu Ayla Arslan Osman Memikoğlu

https://doi.org/10.1501/Tipfak_0000000767

Öz

Anahtar Kelimeler

-

Yeni Bir Antibakteriyel Ajan: DAPTOMİSİN

Öz

Dünya çapında artan antibiyotik direnci nedeniyle gram pozitif bakteri infeksiyonları, özellikle de Metisilin Dirençli S.aureus (MRSA), için yeni tedavi seçeneklerine ihtiyaç duyulmaktadır. Daptomisin ise geniş gram pozitif patojen etkinliğine sahip olan siklik lipopeptit sınıfı bir antimikrobiyaldir. Komplike deri ve yumuşak doku infeksiyonları, Staphylococcus aureus’un etken olduğu bakteriyemi ve sağ kalp infektif endokarditi için onay almıştır. Hızlı bakterisidal etkinliğinin yanında günde tek doz 4-6mg/kg infüzyon şeklinde uygulanmaktadır. Daptomisin ile kullanımda olan diğer geniş gram pozitif etkinliğe sahip olan 3 antibiyotiğin (vankomisin, linezolid, quinupristin-dalfopristin) minimum İnhibitör Konsantrasyonları (MİK) karşılaştırılmış, MİK50 ve MİK90 değerleri daptomisin, vankomisin, linezolid ve quinupristin-dalfopristin için sırasıyla; 0.125mg/L-0.25mg/L, 1mg/L- 1.5mg/L, 0.5mg/L-0.75mg/L ve 0.5mg/L-0.75mg/L olarak hesaplanmıştır. Diğer antibakteriyellere göre en düşük MIC değerine sahip olan daptomisin dirençli gram pozitif patojenlerin neden olduğu infeksiyonların tedavisinde bir terapötik seçenek olarak karşımıza çıkmaktadır

Anahtar Kelimeler

Daptomisin, Lipopeptit, Gram Pozitif Bakteri, Staphylococcus Aureus

Kaynakça

• Tünger A. Staphylococcus aureus: Mikrobiyoloji, Patogenez ve Epidemiyoloji. Ulusoy S, Usluer G, Ünal S, editörler. Önemli ve sorunlu Gram Pozitif Bakteri İnfeksiyonları. 1st ed. Ankara: Bilimsel Tıp Yayınevi; 2004. p.9-22.
• Özaras R, Tabak F. Daptomisin. Klimik Dergisi 2010; 23(2):35-38.
• Smith K, Perez A, Ramage G et al. Comparison of biofilm-assciated cell survival following in vitro exposure of meticillinresistant Staphylococcus aureus biofilms to the antibiotics clindamycin, daptomycin, linezolid, tigecycline and vancomycin. Int J Antimicrob Agents 2009; 33:374-378.
• Silverman JA, Perlmutter NG, Shapiro HM. Antimicrob Agents Chemother 2003; 47: 2538-2544.
• Tedesco KL, Rybak MJ. Daptomycin. Pharmacothe-rapy 2004; 24(1):41-57.
• Hobbs JK, Miller K, O’Neill AJ et al. Conse-quences of daptomycin-mediated membrane damage in Staphylococcus aureus. J Antimicrob Chemother 2008; 62(5):1003-1008.
• Cha R, Grucz RG Jr, Rybak MJ. Daptomycin dose-effect relationship against resistant gram-positive organisms. Antimicrob Agents Chemother 2003;47(5):1598-603.
• Safdar N, Andes D, Craig W. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 2004;48(1):63-68.
• Chakraborty A, Roy S, Loeffler J et al. Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection. J Antimicrob Chemother 2009;64(1):151-158.
• Kosmidis C, Levine DP. Daptomycin: pharmacology and clinical use. Expert Opin Pharmacother 2010;11(4):615-625.
• Silverman JA, Mortin LI, Vanpraagh AD et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005;191(12):2149-2152.
• Raad I, Hanna H, Jiang Y et al. Comparative activities of daptomycin, linezolid and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother 2007;51(5):1656-1660.
• Barry AL, Fuchs PC, Brown SD. In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American Medical Centers. Antimicrob Agents Chemother 2001;45(6):1919-1922.
• Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 2004;38(7):994-1000.
• Critchley IA, Blosser-Middleton RS, Jones ME et al. Baseline study to determine in vitro activities of daptomycin against grampositive pathogens isolated in the United States in 2000-2001. Antimicrob Agents Chemother 2003;47(5):1689-1693.
• Snydman DR, Jacobus NV, McDermott LA et al. Comparative in vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens. Antimicrob Agents Chemother 2000;44(12):3447-3450.
• Yılmaz Bozkurt G, Kutlu H, Aslan A et al. Klinik MRSA izolatlarında in vitro gram pozitif etkinlik: daptomisin, vankomisin, linezolid ve quinupristin/dalfopristin karşılaştırılması. 3.EKMUD Kongre Kitabı; 12-16 Mayıs, 2010; Ankara, Türkiye. S.324.
• Traczewski MM, Katz BD, Steenbergen JN et al. Inhibitory and Bactericidal Activity of Daptomycin, Vancomycin and Teicoplanin against Methicillin-Resistant Staphylococcus aureus Collected from 1985 to 2007. Antimicrob. Agents Chemother 2009;53(5):1735-1738.
• Cha R, Brown WJ, Rybak MJ. Bactericidal Activities of Daptomycin, QuinupristinDalfopristin, and Linezolid against Vancomycin-Resistant Staphylococcus aureus in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations. Antimicrob Agents Chemother 2003;7(12): 3960–3963.
• Crompton JA, North DS, Yoon M et al. Outcomes with daptomycin in the treatment of Staphylococcus aureus infections with a range of vancomycin MICs. Journal of Antimicrobial Chemotherapy 2010; 65(8):1784-1791.
• Arbeit RD, Maki D, Tally FP et al. Daptomycin 98-01 and 99-01 Investigators: The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004;38(12): 1673-1681.
• Davis SL, McKinnon PS, Hall LM et al. Daptomycin versus vancomycin for complicated skin and skin structure infections:clinical and economic outcomes. Pharmacotherapy 2007;27(12):1611-1618.
• Finney MS, Crank CW, Segreti J. Use of daptomycin to treat drug-resistant Grampositive bone and joint infections. Curr Med Res Opin 2005;21(12):1923-1926.
• Rouse MS, Piper KE, Jacobson M et al. Daptomycin treatment of Stapylococcus aureus experimental chronic osteomyelitis. J Antimicrob Chemother 2006;57(2):301-305.
• Forrest GN, Donovan BJ, Lamp KC et al. Clinical experience with daptomycin for the treatment of patients with documented gram-positive septic arthritis. Ann Pharmacother 2008; 42(2): 213-217.
• Fowler VG, Boucher HW, Corey R et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl Med J 2006;355(7):653-665.
• Streit JM, Jones RN, Sader HS. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram positive organisms. J Antimicrob Chemother 2004;53:669-674.
• Friedman L, Alder JD, Silverman JA. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob Agents Chemother 2006;50(6):2137-2145.
• Kaatz GW, Lundstrom TS, Seo SM. Mechansims of daptomycin resistance in Staphylococcus aureus. Int J Antimicrob Agents 2006;28(4):280-287.
• Graber CJ, Wong MK, Carleton HA et al. Intermediate Vancomycin Susceptibility in a Community associated MRSA Clone. Emerging Infectious Diseases 2007;13(3):491-493.